Andrew Hollman Meyer sold $110k of JANX
Chief Business Officer at Janux Therapeutics, Inc.. 3,333 shares at an average of $32.98, traded Dec 1, 2025, filed Dec 3, 2025.
Score components
- +15RoleOfficer
- +10Trade size$110k at market
- 0Share of holdings soldSold 3.8% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -20.2%, 3m -16.1%, 6m -20.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001864159-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 1, 2025 | MOption exercise Common Stock10b5-1 | +3,333 | $10.59 | $35k | 88,307 | Dec 3, 2025 |
| Dec 1, 2025 | SOpen-market sale Common Stock10b5-1 | -2,700 | $32.85 | $89k | 85,607 | Dec 3, 2025 |
| Dec 1, 2025 | SOpen-market sale Common Stock10b5-1 | -633 | $33.52 | $21k | 84,974 | Dec 3, 2025 |
| Dec 1, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,333 | $0.00 | $0 | 114,768 | Dec 3, 2025 |
Related signals
Other insiders at Janux Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | JANXsell Janux Therapeutics, Inc. | Janeen Noel Doyle Chief Corp. & Bus. Dev. Ofcr | $57k 4,059 shares | -5% | |
| 20Weak | JANXsell Janux Therapeutics, Inc. | Maria Dobek Vice President, Accounting | $29k 2,038 shares | -6% | |
| 50Moderate | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $111k 8,072 shares | -3% | |
| 36Weak | Janux Therapeutics, Inc. | Thomas DiRaimondo Chief Scientific Officer | $34k 2,505 shares | -2% | |
| 30Weak | Janux Therapeutics, Inc. | Maria Dobek Vice President, Accounting | $20k 1,462 shares | -9% | |
| 35Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $26k 1,879 shares | -2% | |
| 36Weak | Janux Therapeutics, Inc. | Charles M. Winter Chief Technical Officer | $33k 2,401 shares | -3% | |
| 41Moderate | Janux Therapeutics, Inc. | Zachariah McIver Chief Medical Officer | $37k 2,714 shares | -10% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $100k 3,333 shares | -4% | |
| 3Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $501k 16,665 shares | -17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.